NMDA antagonists for stroke and head trauma: current status

Abstract

The clinical failures with selfotel, cerestat and eliprodil have evoked a significant degree of caution regarding the clinical utility of NMDA antagonists in the treatment of stroke and head trauma. However, clinical studies with these first generation compounds have taught us that significant improvements in the therapeutic indices of NMDA antagonists are required to in order to fully validate or negate the role excessive NMDA neurotransmission in these clinical conditions. Such compounds appear to be entering clinical trials with significant findings expected over the next two years.

• ACEA 1021
• ARL 15896AR
• cerestat
• CP 101605
• CPP-ene
• dexanabol
• eliprodil
• GV 150526A
• head trauma
• Ro 25-6981
• selfotel
• stroke
• ZD 9379